Roivant Sciences Ltd (NAS:ROIV)
$ 12.48 -0.23 (-1.81%) Market Cap: 9.08 Bil Enterprise Value: 3.92 Bil PE Ratio: 2.21 PB Ratio: 1.78 GF Score: 61/100

Roivant Sciences Ltd at Citi BioPharma Conference Transcript

Sep 07, 2023 / 03:20PM GMT
Release Date Price: $11.7 (-0.76%)
Andrew Simon Baum
Citigroup Inc. Exchange Research - Research Analyst

Terrific. Well, delighted to introduce our next session with Roivant. I have the CEO with me, Matt Gline. I have Richard Pulik, the CFO and Investor Relations in the audience today.

So Roivant is a very different type of pharma company with a fairly unique business model, but one that so far has enjoyed some considerable success, both with your marketed agents, but also with 3 agents you have, and I'm just going to say, late-stage development, but that's a bit generous for the mid-late, early late stage...

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

You can call them late stage.

Questions & Answers

Andrew Simon Baum
Citigroup Inc. Exchange Research - Research Analyst

Yes, we can call them. So maybe just starting with the TL1A antagonist and obviously, starting with the Prometheus data, the Merck acquisition and then your data in UC, there's an extraordinary amount of interest in it. And the transaction from your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot